Table 1.
Characteristics evaluated as potential contributors for impact on time to first MACE in US population and non-US populations.
| Demographics | Baseline characteristics | Concomitant medications at baseline | Cardiovascular history and complications at screening |
|---|---|---|---|
| Age | BMI | Antidiabetic medicationa | Cardiovascular risk |
| Gender | Body weight | Antihypertensive medicationb | Prior MI |
| Smoking status | Systolic blood pressure | Diuretics | Prior PCI |
| Race | Diastolic blood pressure | Lipid-lowering drugs | Prior hypertension |
| T2D duration | Heart rate | Platelet aggregation inhibitors | Prior TIA |
| HbA1c | Antithrombotic medication | Prior ischemic heart disease | |
| LDL cholesterol | Prior left ventricular diastolic dysfunction | ||
| HDL cholesterol | Prior carotid artery stenosis | ||
| Total cholesterol | Prior >50% stenosis | ||
| Triglycerides | Peripheral arterial disease | ||
| Renal function | CABG | ||
| Albuminuria |
Each parameter has been analyzed in a Cox model with treatment, the parameter and its interaction with treatment, and the factor US/non-US and its interaction with treatment.
aIncludes the following categories: “1 OAD,” “more than 1 OAD(s),” “insulin + OAD(s),” “insulin – OAD(s),” and “none.”
bIncludes the following categories: “beta-blockers,” “calcium channel blockers,” “loop diuretics,” “renin system blockers,” and “other.”
BMI, body mass index; CABG, coronary artery bypass graft; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MACE, major adverse cardiovascular events; MI, myocardial infarction; OAD, oral antidiabetic drug; PCI, percutaneous coronary intervention; T2D, type 2 diabetes; TIA, transient ischemic attack; US, United States.